Perampanel Drug Asset Due Diligence Report 2026

This Perampanel Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.

Decision date: 15 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.

Approved

Highest phase

153

Registered trials

195

Result records

Matched deals

Executive recommendation: GO

Decision memo

Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.

The central underwriting question is whether Perampanel can convert its Small molecule drug profile and AMPA receptor biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.

1. Asset identity and development status

Asset	Perampanel (query alias: perampanel)
Modality / target	Small molecule drug; AMPA receptor; AMPA receptor antagonists
Highest global status	Approved
Originator	Eisai Co., Ltd.
Active developers	Eisai GmbH, Eisai, Inc., Eisai Europe Ltd.

The MCP disease footprint includes Epilepsies, Partial, Epilepsy, Epilepsy, Idiopathic Generalized. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.

2. Clinical program: design and endpoint audit

Registry	Phase	Status	Enrollment	Lead primary endpoint
JPRN-jRCT1061250057	Phase 2	Recruiting	20	初回手術と比較して2回目手術の病理組織検体においてKi-67 indexが20%以上低下した症例の割合
NCT07284069	Early Phase 1	Recruiting	36	Maximum tolerable dose of senicapoc monotherapy (mg)
JPRN-jRCTs031250725	Phase 1	募集中	20	Confirmation of the occurrence of adverse events (type, frequency, severity, and relationship to the investigational drug).

The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.

Reproduce the asset-to-trial workflow with PatSnap MCP

3. Clinical readouts: what is known

Effect of adjunctive perampanel on daytime sleepiness and quality of life in adults with focal–onset seizures: Post hoc analyses of the AMPA study

Not Applicable; n=202; evaluation: Positive. Reported fields: ESS(end of treatment) = 6.2 point

Analysis of Excessive Daytime Sleepiness Caused by Anti-seizure Medications: A Single Tertiary Center Experience in Japan (P9-9.015)

Not Applicable; n=207; evaluation: Positive. Reported fields: Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. ; Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients. ; Adverse Event: excessive daytime sleepiness = Among newer ASMs, there are differences in their tendency to cause excessive daytime sleepiness, with Clonazepam and Levetiracetam being more commonly associated with this side effect, thus warranting caution. Conversely, Perampanel and Lacosamide are less likely to cause daytime sleepiness, and ASM selection should be tailored to the sleep characteristics of epileptic patients.

Pilot Study of Perampanel on Peritumoral Hyperexcitability and Seizure Control in Newly Diagnosed High Grade Glioma

Phase 1/2; n=12; evaluation: not stated. Reported fields: Peritumoral HFO Rate(Mean) = 1.4 HFOs per minute (Full Range, 0.4 - 3.0); Peritumoral HFO Rate(Mean) = 2.5 HFOs per minute (Full Range, 0 - 5.6); -

These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.

4. Market and competitive position

Perampanel addresses Epilepsies, Partial, Epilepsy, Epilepsy, Idiopathic Generalized. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Small molecule drug—must demonstrate a benefit large enough to offset class-specific safety and operational costs.

The strongest market-validation signal in this screen is partner behavior: 4 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.

5. Transaction precedent and economics

Date	Transaction	Phase at deal	Disclosed economics
2026-05-07	Angelini Pharma to Acquire Catalyst Pharmaceuticals for 4.1 Billion USD (3.5 Billion Euros), Entering the U.S. Market and Consolidating its Leadership in Brain Health and Rare Disease	Approved	US$4,100.0M stated total
2022-12-19	Catalyst Pharmaceuticals to Acquire U.S. Commercial Rights to FYCOMPA® (Perampanel) CIII From Eisai Co., Ltd	Approved	US$160.0M upfront
2017-10-03	Eisai to commercialize Grupo Biotoscana's Halaven, Lenvima, Fycompa and Inovelon in Latin America	Approved	Financial terms not disclosed

Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.

6. IP and freedom-to-operate screen

The milestone feed surfaced a patent-application signal described as “Perampanel pharmaceutical composition and preparation thereof”. The milestone feed surfaced a patent-application signal described as “Preparation method of perampanel fine granules”. The milestone feed surfaced a patent-application signal described as “Perampanel microspheres based on multiple emulsion process as well as preparation method and application of perampanel microspheres”.

The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.

7. Principal risks and diligence gates

Therapeutic index across KRAS/BRAF mutation subgroups
On-target toxicity and adaptive MAPK resistance
Lack of matched efficacy results in the current MCP result set

Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.

8. Final go/no-go memorandum

GO